ArticleHealth affairs (Project Hope)2025
Key-Informant Perspectives On Pharmacy-Based Methadone Treatment For Opioid Use Disorder In The US.
Article in Health affairs (Project Hope), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treating Opioid Use Disorder With Methadone in Pharmacies.JAMA network open · 2026Article
- "Now that I'm here, I actually have the stability and the time to really think about stuff like that": Perspectives on medications for opioid use disorder in low-threshold harm reduction housing.Journal of substance use and addiction treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Access to medications for opioid use disorder (OUD) in the pharmacy is internationally accepted; however, in the US, methadone treatment for OUD can only be provided by opioid treatment programs (OTPs). Under current US law, OTPs and pharmacies can partner to offer methadone in the pharmacy through "medication units." Changes to federal law could permit pharmacies to fill methadone prescriptions for OUD. To identify the advantages, disadvantages, barriers, and facilitators of pharmacy-based methadone treatment, we conducted interviews from April through July 2024 with thirty-one key informants, representing people with methadone treatment experience, OTP and pharmacy leadership, payers, and policy makers. Pharmacy-based methadone treatment was viewed favorably by all groups. People receiving OUD treatment embraced pharmacy-based methadone over models perpetuating restrictive OTP practices. Key facilitators included support for change, sustainable payment models, and clear regulations. Barriers included stigma, financial obstacles, and unclear regulations. Legislative and regulatory changes could expand access to methadone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.